Absci Corporation (NASDAQ:ABSI) shares surged 24% on Wednesday after the biotechnology company reported encouraging interim Phase 1 safety data for ABS-201, its experimental antibody treatment for hair loss.
The results provided an early boost to investor confidence as the company advances the candidate through clinical development for androgenetic alopecia, the most common form of hair loss.
Phase 1 Trial Meets Key Safety Objectives
According to Absci, ABS-201 was generally well tolerated across all blinded single ascending dose cohorts evaluated in the ongoing study.
The trial enrolled 32 healthy adult participants who received intravenous doses ranging from 150 mg to 1,800 mg across four separate cohorts.
The company reported no serious adverse events during the study.
Most treatment-emergent adverse events were classified as mild, with the only moderate event being a headache reported in the third cohort. Investigators determined that the event was unlikely to be related to the treatment.
The favorable safety profile supports continued development of the therapy and progression into subsequent stages of testing.
ABS-201 Targets Androgenetic Alopecia
ABS-201 is an anti-prolactin receptor antibody being developed to treat androgenetic alopecia, a condition that affects an estimated 80 million people in the United States.
The therapy is designed to target biological pathways associated with hair loss and could offer a differentiated treatment approach compared with currently available options.
Pharmacokinetic data from the study indicated an estimated half-life of at least 65 days.
According to the company, the long duration of activity could support a treatment schedule involving only two or three injections over a six-month period.
Multiple-Dose Study Already Underway
Following the positive initial safety findings, Absci has begun enrolling participants in the first multiple ascending dose cohort involving individuals diagnosed with androgenetic alopecia.
The next stage of the study is expected to provide important insights into the drug’s efficacy and its ability to promote meaningful clinical improvements in hair growth.
Management expects to release interim proof-of-concept results during the second half of 2026.
Full proof-of-concept data are anticipated in early 2027.
Company Raises $100 Million to Support Development Pipeline
Alongside the clinical update, Absci announced the pricing of an underwritten public offering consisting of 13.5 million shares.
The shares were priced at $7.41 each and are expected to generate gross proceeds of approximately $100 million before underwriting fees and related expenses.
The financing attracted participation from several prominent healthcare and institutional investors, including Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile and another large investment management firm.
Funding to Advance Hair Loss and Endometriosis Programs
Absci said the proceeds will be used to support the continued development of ABS-201 in both androgenetic alopecia and endometriosis.
The company also plans to launch a Phase 2 clinical trial for endometriosis later this year.
The successful financing strengthens Absci’s balance sheet and provides additional resources to advance multiple programs through key clinical milestones.
Investors Focus on Upcoming Efficacy Data
The strong market reaction reflects growing investor optimism following the positive safety results and the company’s ability to secure significant new capital.
With proof-of-concept data expected over the next 12 months and additional clinical studies planned, investors are increasingly focused on whether ABS-201 can demonstrate meaningful efficacy in treating hair loss and support its potential as a future commercial product.
The latest results mark an important step forward for the program as Absci continues building its clinical pipeline in areas of significant unmet medical need.